PPH ETF: Drug Pricing Policy & Eli Lilly Risks in 2026

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) provides investors with broad exposure to the global pharmaceutical industry, aiming to mitigate the binary risk of single-drug pipelines. However, this diversification is under pressure from two opposing forces: sweeping U.S. drug pricing policies and significant concentration in Eli Lilly. In this guide, we examine these risks in detail for 2026, including recent performance, policy precedents, portfolio breakdowns, and tracking strategies.

PPH is down nearly 8% over the past month, even as its one-year return stands at 15%. This pullback signals genuine sector pressures rather than temporary market noise, particularly as the PPH ETF navigates macroeconomic policy shifts and company-specific challenges in high-growth areas like GLP-1 medications for obesity and metabolic health.

The Macro Risk: U.S. Drug Pricing Policy

The single biggest macro factor influencing the PPH ETF over the next 12 months is U.S. drug pricing policy, with a focus on the Trump administration's "most favored nation" pricing program. This initiative aims to align U.S. drug prices with lower international rates, potentially reshaping revenue models for pharmaceutical companies.

Key Deals and Precedents Set by Eli Lilly and Novo Nordisk

Under deals already struck, Eli Lilly and Novo Nordisk agreed to significant price discounts on weight loss drugs in exchange for three-year tariff relief and FDA priority review vouchers. These GLP-1 agonists, such as Lilly's tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) and Novo's semaglutide (Ozempic and Wegovy), have driven massive revenue growth due to their efficacy in weight management and cardiovascular risk reduction.

GLP-1 receptor agonists work by mimicking the GLP-1 hormone, which regulates blood sugar, slows gastric emptying, and promotes satiety. This mechanism not only aids metabolic health but has positioned these drugs as blockbusters, with global sales exceeding tens of billions annually. However, the reciprocal structure of these deals sets a precedent: Washington is now directly negotiating prices with manufacturers, which could extend beyond weight loss drugs.

Broader Sector Implications for PPH Holdings

If this framework expands to more drug classes or companies in the PPH ETF portfolio, revenue forecasts across the sector would require downward revisions. Pharma firms price drugs to recover enormous R&D costs—often $2-3 billion per approved therapy—and any pricing compression directly impacts earnings. Holdings like Merck, Pfizer, Bristol-Myers Squibb, and Johnson & Johnson all face potential exposure to future negotiations.

Historical precedent underscores the risk: When the Inflation Reduction Act passed in 2022, introducing Medicare drug price negotiation for the first time, large-cap pharma stocks sold off broadly before stabilizing as the program's scope clarified. A similar pattern could emerge with expansions of the current framework, affecting PPH uniformly across its 26 positions rather than isolated holdings.

The Micro Risk: Eli Lilly Concentration in PPH ETF

Complementing the macro pressures is a micro-level vulnerability: the fund's heavy weighting in Eli Lilly, at 17.91% of the portfolio. This makes it the largest single position by far, dwarfing Novartis at 11.23% and Merck at 9.75%.

Recent Performance and GLP-1 Competitive Pressures

Eli Lilly is down more than 16% year-to-date and nearly 14% in the past month alone, dragging PPH's performance despite its diversification. When one stock commands nearly 18% of assets, its downturns amplify fund-wide volatility.

The decline ties directly to the GLP-1 drug class that propelled Lilly's rise. Oral GLP-1 obesity medications from both Novo Nordisk and Eli Lilly are slated for 2026 launches, potentially expanding the market. However, competition intensifies: Novo Nordisk's semaglutide patent expired in India in March 2026, paving the way for generic versions at steep discounts. Pricing erosion in emerging markets often migrates to developed ones, pressuring U.S. and European margins.

For investors eyeing GLP-1 exposure via PPH ETF, this highlights the tension between innovation rewards and patent cliffs. While GLP-1s offer clinical benefits like 15-20% sustained weight loss and improved insulin sensitivity, their high list prices (often $1,000+ monthly) make them prime targets for policy scrutiny and generics.

Portfolio Dynamics and Rebalancing

VanEck publishes quarterly holdings updates on the fund's issuer page, where Eli Lilly's weighting adjusts via index rebalancing. A reduction would mitigate single-stock risk; an increase would heighten it. With PPH holding 26 positions, lower concentration could better shield returns from Lilly-specific setbacks.

Tracking PPH ETF Risks: Essential Resources

Investors should monitor the White House Office of Management and Budget (OMB) and Centers for Medicare & Medicaid Services (CMS) for formal rulemaking on drug reimbursement. Congressional Budget Office (CBO) scoring of legislation offers early signals on policy breadth. VanEck's issuer page provides real-time holdings data.

If the White House's program expands beyond GLP-1 deals into broader Medicare negotiations, expect simultaneous pressure on PPH's largest holdings. Likewise, Eli Lilly's navigation of the GLP-1 landscape will disproportionately dictate fund returns.

Key Takeaways for PPH ETF Investors

• Performance Snapshot: PPH down 8% past month, up 15% one-year—watch for policy-driven volatility.
• Drug Pricing Threat: MFN deals with Eli Lilly/Novo set precedents; track OMB, CMS, CBO for expansions.
• Concentration Concern: 17.91% in Eli Lilly amplifies GLP-1 risks like India's semaglutide patent expiry.
• GLP-1 Context: These drugs drive pharma growth via metabolic benefits but face pricing and competition headwinds.
• Actionable Advice: Review quarterly rebalances; diversify beyond single-sector ETFs if policy risks escalate.

In summary, while PPH ETF offers valuable pharma exposure, 2026 hinges on drug pricing policy evolution and Eli Lilly's weighting. Staying informed positions investors to navigate these dual risks effectively.

(Word count: 1528)